金城医药公告，控股子公司广东金城金素制药有限公司及其全资子公司广东榄都药业有限公司收到国家 税务总局中山市税务局下发的《税务处理决定书》，根据税务部门对金城金素及榄都药业2017年和2018 年纳税情况的检查，金城金素及榄都药业应补缴税款及滞纳金共计2159.68万元。截至本公告披露日， 金城金素及榄都药业的税款及滞纳金已缴纳完毕。本次补缴不涉及行政处罚。 ...

上海海欣集团股份有限公司控股子公司江西赣南海欣药业股份有限公司近日获得国家药品监督管理局核 准签发的化学药品"维生素B6注射液"的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效 一致性评价。维生素B6注射液为国家医保甲类品种和国家基药目录品种，2024年全国公立医疗机构销 售额约为3.04亿元。此次通过一致性评价有助于提升产品市场竞争力，但对公司当前经营业绩不会产生 重大影响。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总：控股子公司维生素B6注射液通过仿制药一致性评价 公司公告汇总：维生素B6注射液为国家医保甲类品种，2024年全国公立医疗机构销售额约3.04亿 元 公司公告汇总：此次通过评价有助于提升产品市场竞争力，但对当前经营业绩无重大影响 本周关注点 公司公告汇总 截至2025年12月26日收盘，海欣股份（600851）报收于7.01元，较上周的7.13元下跌1.68%。本周，海 欣股份12月23日盘中最高价报7.24元。12月26日盘中最低价报7.0元。海欣股份当前最新总市值84.61亿 元，在化学 ...

Core Viewpoint - ST Fuhua has faced regulatory penalties due to financial misreporting, which has resulted in significant adjustments to its reported profits for previous years [1][2]. Company Announcements Summary - ST Fuhua was penalized by the China Securities Regulatory Commission (CSRC) for failing to properly account for operating costs in 2019 and 2020, leading to an inflated profit of a total of 53.24 million yuan [2]. - The 2023 annual report reported an underestimation of asset impairment losses amounting to 27.82 million yuan, resulting in a profit inflation ratio of 118.48% [2]. - The company has been fined 4 million yuan, while its chairman, Song Zheng, has been fined 500,000 yuan [2].

截至2025年12月26日收盘，首药控股（688197）报收于35.3元，较上周的37.04元下跌4.7%。本周，首 药控股12月22日盘中最高价报37.55元。12月26日盘中最低价报35.2元。首药控股当前最新总市值52.5亿 元，在化学制药板块市值排名97/151，在两市A股市值排名3231/5178。 公司公告汇总 首药控股（北京）股份有限公司于近日收到政府补助款项6,000.00万元，属于与收益相关的政府补助。 公司根据《企业会计准则第16号——政府补助》等相关规定，确认上述事项并划分补助类型。该补助未 经审计，具体会计处理及对公司相关年度损益的影响以审计机构年度审计确认结果为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 本周关注点 公司公告汇总：首药控股收到6,000.00万元与收益相关的政府补助。 ...

Core Viewpoint - The company has integrated industrial robots into some of its production lines to enhance automation and efficiency, aligning with the trend of smart manufacturing [1] Group 1 - The company confirmed the use of industrial robots in part of its production lines [1] - The application of robots is aimed at improving production automation levels and efficiency [1] - This initiative is in line with the development direction of smart manufacturing [1]

证券日报网讯 12月26日，海南海药发布公告称，公司2025年12月26日召开2025年第六次临时股东会， 审议通过《关于修订并更名为的议案》等。 （文章来源：证券日报） ...

根据收到的《告知书》认定情况，公司股票可能被实施重大违法强制退市，公司股票于12月29日(星期 一)起被叠加实施退市风险警示。 人民财讯12月26日电，*ST长药（300391）12月26日公告，公司及相关人员收到中国证监会《行政处罚 事先告知书》。经查，*ST长药2021年、2022年、2023年连续三年虚增收入和利润，违反证券法律法 规。证监会拟对公司罚款1000万元，对14名责任人合计罚款3100万元，对公司原总经理罗明采取终身证 券市场禁入措施，对当事人杨正辉采取10年证券市场禁入措施。 ...

华润双鹤公告称，公司于2025年12月25日召开董事会会议，审议通过使用自有闲置资金办理理财及定期 存款的议案。公司拟购买保本型银行结构性存款产品或低风险等级银行理财产品（不含珠海华润银 行），投资金额不超5亿元，资金可滚动使用，单笔期限不超6个月，投资期限自董事会批准日起1年。 该事项属董事会决策权限，无需提交股东会审批。理财可能面临多种风险，公司将采取风控措施。理财 对主营业务无重大影响，收益将增加净利润。 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.49% on December 26, with Sunflower leading the drop [1] - The Shanghai Composite Index closed at 3963.68, up 0.1%, while the Shenzhen Component Index closed at 13603.89, up 0.54% [1] Stock Performance - Notable gainers included: - Hongyuan Pharmaceutical (301246) with a closing price of 26.88, up 20.00% and a trading volume of 476,800 shares, totaling 1.216 billion yuan [1] - Fuxiang Pharmaceutical (300497) closed at 16.08, up 6.70% with a trading volume of 889,200 shares, totaling 1.4 billion yuan [1] - Key stocks with positive performance also included Keyuan Pharmaceutical (301281), Kangzhiyue Pharmaceutical (300086), and Ailisi (688578) [1] - Major decliners included: - Sunflower (300111) with a closing price of 6.36, down 10.80% and a trading volume of 1,429,900 shares, totaling 899 million yuan [2] - Xinnoway (300765) closed at 36.88, down 6.77% with a trading volume of 189,500 shares, totaling 711 million yuan [2] - Other notable declines were seen in Shouyao Holdings (688197) and Kelun Pharmaceutical (002422) [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.096 billion yuan from institutional investors, while retail investors contributed a net inflow of 914 million yuan [2] - The capital flow data indicates that: - Hongyuan Pharmaceutical had a net inflow of 230 million yuan from institutional investors, while retail investors had a net outflow of 127 million yuan [3] - Fuxiang Pharmaceutical experienced a net inflow of 178 million yuan from institutional investors, with a net outflow of 140 million yuan from retail investors [3] - Other companies like Shutaishen (300204) and Kangzhiyue (300086) also showed varied capital flows [3]

Core Viewpoint - The company Sunflower (300111.SZ) is facing scrutiny from the Shenzhen Stock Exchange regarding its proposed acquisition of semiconductor materials company Xipu Materials, raising concerns about the asset quality and operational capacity of the target company [1][2]. Group 1: Acquisition Details - Sunflower plans to acquire 100% equity of Xipu Materials through a combination of issuing shares and cash payments, as disclosed in its asset acquisition proposal [1]. - Xipu Materials, based in Fujian, operates under a model that combines customized processing and self-production, serving as a core supplier to various wafer fabs [1]. - The core products of Xipu Materials include high-purity electronic specialty gases and silicon-based precursors, with a complete product matrix covering mainstream electronic gases and precursors [1]. Group 2: Regulatory Concerns - The Shenzhen Stock Exchange has requested detailed financial information from Xipu Materials, including revenue, costs, and gross margins for 2023 and 2024, as well as specifics on transactions with related parties [2]. - There are concerns regarding potential legal issues affecting Xipu Materials, particularly a lawsuit against its actual controller, which could impact the company's operations and asset transfer [2]. Group 3: Market Reaction and Company Background - Following the announcement of the scrutiny, Sunflower's stock price dropped significantly, opening down 16% and closing at 6.36 yuan, a decrease of 10.80% [2]. - Sunflower's main business is in pharmaceuticals, with a focus on anti-infection drugs and cardiovascular medications, facing challenges due to ongoing healthcare reforms and price pressures [3]. - The company aims to diversify into the high-end semiconductor materials sector to create a dual business model, enhancing its profitability and sustainability [3].